Trial reportThe journal of allergy and clinical immunology. In practice2026
Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes.
Trial report in The journal of allergy and clinical immunology. In practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Codfish Oral Immunotherapy in Children Aged 2-10: Randomized Placebo-Controlled Study.Allergy · 2026Trial
- Predictive Biomarkers for Sustained Unresponsiveness Following Oral Immunotherapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPeanut oral immunotherapy (pOIT) is a recognized treatment for patients with peanut allergy, though not all patients who undergo this therapy achieve desensitization or remission.
objectiveTo determine whether missed doses or dosing reactions predict clinical outcomes with pOIT.
methodsData from IMPACT (Oral Immunotherapy for Induction of Tolerance in Peanut Allergic Children trial), a randomized, double-blind, placebo-controlled trial of pOIT in children aged 1 to 4 years with peanut allergy, were analyzed to determine whether treatment-emergent variables influence desensitization (ability to consume 5000 mg of peanut protein without reaction during a blinded oral food challenge after 134 weeks of pOIT) and remission (6 months after discontinuation of pOIT). Logistic regression models, controlling for age and Ara h2-specific IgE, were performed to assess the relationship between dosing reactions, missed doses, and outcomes.
resultsConsecutive missed doses during build-up significantly correlated with reduced likelihood of desensitization (P = .03; odds ratio [OR], 0.69; 95% CI, 0.49-0.96), whereas consecutive missed doses during maintenance did not (P = .10; OR, 0.79; 95% CI, 0.59-1.05). Furthermore, the total individual missed doses did not significantly correlate with desensitization or remission in either phase of pOIT. Conversely, dosing reactions during maintenance did significantly correlate with reduced likelihood of desensitization (P = .01; OR, 0.71; 95% CI, 0.54-0.93), whereas dosing reactions during build-up did not significantly correlate with desensitization (P = .57; OR, 0.95; 95% CI, 0.79-1.14). Fewer than 10% of missed doses were attributed to dosing reactions.
conclusionsMissed doses during therapy and dosing reactions during maintenance associated with poorer pOIT outcomes. Clinicians should support adherence during build-up and consider dose adjustments for patients having dosing reactions during maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.